Expand all sections

Ozenoxacine

Ozenoxacin Ferrer

Extended indication Korte termijnbehandeling van niet-bulleuze impetigo (krentenbaard) bij volwassenen, adolescenten en
Therapeutic value Possibly no place in the treatment regimen
Registration phase Clinical trials

Product

Active substance Ozenoxacine
Domain Infectious diseases
Reason of inclusion New medicine (specialité)
Main indication Bacterial infections
Extended indication Korte termijnbehandeling van niet-bulleuze impetigo (krentenbaard) bij volwassenen, adolescenten en kinderen vanaf 2 jaar.
Proprietary name Ozenoxacin Ferrer
Manufacturer Ferrer Internat
Mechanism of action Antibiotic
Route of administration Cutaneous
Therapeutical formulation Cream
Budgetting framework Extramural (GVS)
Additional remarks Non-fluorinated quinolone antibacterial agent.

Registration

Registration route Centralised (EMA)
Submission date 2021
Expected Registration 2022
Orphan drug No
Registration phase Clinical trials
Additional remarks Vervolgonderzoek gewenst door CBG naar het risico op de ontwikkeling van antibioticaresistentie per juli 2017. Goedgekeurd door de FDA en in Canada.

Therapeutic value

Current treatment options Verschillende antibiotica
Therapeutic value Possibly no place in the treatment regimen
Substantiation Geen meerwaarde verwacht. Genoeg behandelmethoden dus weinig plek. (Gelijke waarde niet aan te geven gezien de vergelijkende behandeling in de studies placebo-vehicle is).
Duration of treatment Average 5 day / days
Frequency of administration 2 times a day

Expected patient volume per year

Additional remarks Aantal patiënten heel klein.

Expected cost per patient per year

References app.aafp.org
Additional remarks De kosten van een tube van 30-gram 1% ozenoxacin crème kost in de Verenigde Staten $320.

Potential total cost per year

There is currently nothing known about the possible total cost.

Off label use

There is currently nothing known about off label use.

Indication extension

Indication extension No

Other information

There is currently no futher information available.